arrow
M

Michela Palleschi

Universita degli Studi di Bari Aldo Moro
H指数:14
被引数:640

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Unraveling the use of vaccine therapy in HER-2 positive breast cancer: a comprehensive review of current state and future perspectives

解构疫苗疗法在HER-2阳性乳腺癌中的应用:当前状态和未来展望的全面综述

2026-07-250
OA
Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: an international real-world analysis with propensity-score matching

根据Prosigna®评估年轻患者中I-II期ER+/HER2阴性乳腺癌化疗使用与预后的关联:一项基于倾向性评分匹配的国际真实世界分析

2026-05-220
OAAI
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone Metastases

CDK4/6抑制剂在HR+/HER2-骨转移性乳腺癌患者中的真实世界无进展生存比较

2026-05-010
OA
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients

质子泵抑制剂与CDK4/6抑制剂abemaciclib联用不影响转移性乳腺癌患者的临床结局

2026-04-220
PRE
Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2− Breast Cancer: A Systematic Review

解锁免疫检查点抑制剂在HR+/HER2−乳腺癌中的潜力:一项系统综述

2025-09-230
OAAI
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants

探索三阴性乳腺癌患者中癌症易感基因的启动子区域,发现存在罕见的胚系变异。

2025-05-080
OA
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity

转移性乳腺癌患者循环肿瘤细胞的转录组学分析揭示了其生物学特征和表型异质性的新线索

2025-05-060
OA
Hormonal Therapy In Endometriosis And Breast Cancer Risk Propensity Score-Matched Real-World Analysis

子宫内膜异位症中的激素疗法与乳腺癌风险倾向评分匹配的真实世界分析

2025-02-010
PRE
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (vol 10, 58, 2024)

药物-药物相互作用对abemaciclib在AB-意大利研究的真实世界经验中的临床影响 (第10卷,58卷,2024)

2024-08-020
OAAI
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

在AB-意大利研究的现实世界经验中,药物-药物相互作用对abemaciclib的临床影响

2024-07-173
OAAI
Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
2024-05-020
PRE